research use only

Busulfan Thioredoxin Reductase Inhibitor

Cat.No.S1692

Busulfan is a cell cycle non-specific alkylating antineoplastic agent. It causes DNA damage by cross-linking DNAs and DNA and proteins. Busulfan inhibits thioredoxin reductase activity. It also induces apoptosis. It is an immunosuppressive and myeloablative chemotherapeutic agent.Busulfan (NSC-750) can be used to induce animal models of Anemia.
Jump to

Quality Control

Batch: Purity: 99.81%
99.81

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SK-N-SH cells Proliferation assay 10-100 μM 72 h Antiproliferative activity against human SK-N-SH cells at 10 to 100 uM after 72 hrs by MTT assay 24814532
SiMa cells Proliferation assay 10-100 μM 72 h Antiproliferative activity against human SiMa cells at 10 to 100 uM after 72 hrs by MTT assay 24814532
Kelly cells  Proliferation assay 10-100 μM 72 h Antiproliferative activity against human Kelly cells at 10 to 100 uM after 72 hrs by MTT assay 24814532
LS cells Proliferation assay 10-100 μM 72 h Antiproliferative activity against human LS cells at 10 to 100 uM after 72 hrs by MTT assay 24814532
K562 Apoptosis assay 48 hrs Induction of apoptosis in imatinib mesylate-resistant human K562 cells after 48 hrs 18339455
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 49 mg/mL (198.94 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 246.3 Formula

C6H14O6S2

Storage (From the date of receipt)
CAS No. 55-98-1 Download SDF Storage of Stock Solutions

Synonyms NSC-750 SMILES CS(=O)(=O)OCCCCOS(=O)(=O)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro

Busulfan inhibits the cobblestone area-forming cell frequency but fails to cause a significant increase in apoptosis in hematopoietic stem cell alike cells and progenitors. This compound inhibits the hematopoietic function of HSC alike cells and progenitors via an apoptosis-independent mechanism. It induces bone marrow hematopoietic cell senescence associated with an increased expression of p16Ink4a and p19Arf in a time-dependent manner. This chemical, an alkylating agent that causes DNA damage by cross-linking DNAs and DNA and proteins, induces senescence in normal human diploid WI38 fibroblasts through the extracellular signal-regulated kinase (Erk) and p38 mitogen-activated protein kinase (p38 MAPK) cascade independent of the p53-DNA damage pathway. It induces a transient reduction in GSH but a continuous increase in ROS production. This compound-induced hypophosphorylation of Rb prevents apoptosis of spermatogonial stem cells by inhibiting PCNA expression in testicular cells.

In vivo

Busulfan-treated mice exhibit a marked increase in apoptosis and a decrease in testis weight. This compound is administered at the rate of 40 mg/kg body weight to induce a maximal number of apoptotic cells while minimizing the number of necrotic cells. Its conditioning and irradiation results in comparable sensitivity of HSC detection as evaluated by limiting dilution analysis in NOD/SCID mice. This chemical-transplanted mice has slow and incomplete lymphoid engraftment. It (20 mg/kg to 100 mg/kg) provides dose-dependent congenic lymphoid reconstitution in mice.

References
  • [4] https://pubmed.ncbi.nlm.nih.gov/17018389/
  • [5] https://pubmed.ncbi.nlm.nih.gov/17018389/
  • [6] https://pubmed.ncbi.nlm.nih.gov/22286157/

Applications

Methods Biomarkers Images PMID
Western blot p-Y534 AR / AR Ack1 / Src
S1692-WB1
27904688
Growth inhibition assay Cell viability
S1692-viability1
24815002

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-02-13)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03538899 RECRUITING
Severe Combined Immunodeficiency
University of California, San Francisco
2018-05-31 PHASE1; PHASE2
NCT06851767 ENROLLING_BY_INVITATION
X-linked Severe Combined Immunodeficiency; X-SCID; XSCID
National Institute of Allergy and Infectious Diseases (NIAID)
2025-05-09 PHASE1; PHASE2
NCT07524530 NOT_YET_RECRUITING
Core Binding Factor Alpha Subunits; Hematologic Neoplasms; Leukemia; Lymphoma
National Cancer Institute (NCI)
2026-09-09 PHASE2
NCT05565105 NOT_YET_RECRUITING
Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Acute
Guenther Koehne
2026-06 PHASE2
NCT05617625 SUSPENDED
Myelodysplastic Syndromes; Graft Vs Host Disease; Graft-versus-host-disease
Guenther Koehne
2026-06 PHASE2
NCT01306019 RECRUITING
X-linked Severe Combined Immunodeficiency (XSCID)
National Institute of Allergy and Infectious Diseases (NIAID)
2012-09-25 PHASE1; PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can I reconstitute it for in vivo studies?

Answer:
This compound also can be dissolved in 2% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5mg/ml as a clear solution. When preparing the solution, please dissolve it in DMSO clearly first. Then add PEG and Tween. After they mixed well, dilute with water. It in this formulation is not suitable for long-term storage. Please make the fresh solution each time before use.